Direct inhibition of FGFR with infigratinib has also been investigated in preclinical models of SDH-deficient GIST, where it resulted in complete suppression of tumor growth in vivo throughout the dosing period [26]. This evidence concerns the gene SDHB and gastrointestinal stromal tumor.